Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts

European Journal of Pharmacology

Volumn 400, Issue 1, 2000, Pages 113-119

  Uchida, Kazuhiko ^a   Ogino, Kazuhide ^a   Shimoyama, Masaki ^a   Hisatome, Ichiro ^a   Shigemasa, Chiaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Coronary vasorelaxant; Heart; Hemodynamics; Prostaglandin; Thiazolidinedione

Indexed keywords

ALPHA TOCOPHEROL; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; REGLITAZAR; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DRUG EFFECT; HEART HEMODYNAMICS; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE PRESSURE; HEART RATE; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; HYPOGLYCEMIC AGENTS; INDOMETHACIN; ISOXAZOLES; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PERFUSION; PROSTAGLANDINS; RATS; RATS, WISTAR; THIAZOLES; THIAZOLIDINEDIONES; VITAMIN E;

EID: 0034648076     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00359-9     Document Type: Article

References (30)

1. Buchanan T.A., Thawani H., Kades W., Modrall J.G., Weaver F.A., Laurel C., Poppiti R., Xiang A., Hsueh W.A. Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. J. Clin. Invest. 92:1993;720-726.
2. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., Scott S., Rude R.K., Hsueh W.A. Blood pressure lowering by pioglitazone - evidence for a direct vascular effect. J. Clin. Invest. 96:1995;354-360.
3. Ciaraldi T.P., Glimore A., Olefsky J., Goldberg M., Heidenreich K.A. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism. 39:1990;1056-1062.
4. Defronzo R.A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14:1991;173-194.
5. Després J.P., Lamarche B., Mauriège P., Cantin B., Dagenais G.R., Moorjani S., Lupien P.J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334:1996;952-957.
6. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Diabetes. 37:1988;1549-1558.
7. Fujiwara T., Ohsawa T., Takahashi S., Ikeda K., Okuno A., Ushiyama S., Matsuda K., Horikoshi H. Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats. Life Sciences. 63:1998;2039-2047.
8. Ghazzi M.N., Perez J.E., Antonucci T.K., Driscoll J.H., Huang S.M., Faja B.W., Whitcomb R.W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 46:1997;433-439.
9. Herings R.M., de Boer A., Stricker B.H., Leufkens H.G., Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 345:1995;1195-1198.
10. Iwamoto Y., Kuzuya T., Matsuda A., Awata T., Kumakura S., Inooka G., Shiraishi I. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1991;1083-1086.
11. Kaufman L.N., Peterson M.M., DeGrange L.M. Pioglitazone attenuates diet-induced hypertension in rats. Metabolism. 44:1995;1105-1109.
12. Kawasaki J., Hirano K., Nishimura J., Fujishima M., Kanaide H. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation. 98:1998;2446-2452.
13. Kemnitz J.W., Elson D.F., Roecker E.B., Baum S.T., Bergman R.N., Meglasson M. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes. 43:1994;204-211.
14. Laakso M., Edelman S.V., Brechtel G., Baran A.D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J. Clin. Invest. 85:1990;1844-1852.
15. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1994;1188-1193.
16. Ogihara T., Rakugi H., Ikegami H., Mikami H., Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. 8:1995;316-320.
17. Ogino K., Burkhoff D., Bilezikian J.P. The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology. 136:1995;3024-3030.
18. Pollare T., Lithell H., Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med. 321:1989;868-873.
19. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
20. Saku K., Zhang B., Ohta T., Arakawa K. Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am. J. Hypertens. 10:1997;1027-1033.
21. Shibata T., Matsui K., Yonemori F., Wakitani K. JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin resistant models. Br. J. Pharmacol. 125:1998;1744-1750.
22. Shimoyama M., Ogino K., Tanaka Y., Ikeda T., Hisatome I. Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes. 48:1999;609-615.
23. 2+ currents and not endothelial nitric oxide production. Diabetes. 46:1997;659-664.
24. Sung B.H., Izzo J.L.Jr., Dandona P., Wilson M.F. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 34:1999;83-88.
25. Suter S.L., Nolan J.J., Wallance P., Gumbiner B., Olefsky J.M. Metabolic effects of a new oral hypoglycemic agent, CS-045, in non-insulin dependent diabetic subjects. Diabetes Care. 15:1992;193-203.
26. Suzuki M., Hirose J., Asakura Y., Sato A., Kageyama A., Harano Y., Omae T. Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by an α1-blocker (bunazosin). Am. J. Hypertens. 5:1992;869-874.
27. Tomiyama H., Kushiro T., Abeta H., Ishii T., Takahashi A., Furukawa L., Asagami T., Hino T., Saito F., Otsuka Y., Kurumatani H., Kobayashi F., Kanmatsuse K., Kajiwara N. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension. 23:1994;450-455.
28. Walker A.B., Naderali E.K., Chattington P.D., Buckingham R.E., Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes. 47:1998;810-814.
29. Yoshioka S., Nishino H., Shiraki T., Ikeda K., Koike H., Okuno A., Wada M., Fujiwara T., Horikoshi H. Antihypertensive effects of CS-045 treatment in obese zucker rats. Metabolism. 42:1993;75-80.
30. Zhang F., Sowers J.R., Ram J.L., Standley P.R., Peuler J.D. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension. 24:1994;170-175.